CBLI - Cleveland BioLabs, Inc.

Cleveland BioLabs, Inc. (CBLI) was a publicly-traded biopharmaceutical company that focused on the development of drugs for cancer and other diseases. The company was founded in 2003 and was headquartered in Buffalo, New York.

However, as of 2021, CBLI has merged with Cytocom, Inc. and is no longer a publicly-traded company. Prior to the merger, the company developed drugs based on its proprietary technology platforms, including curaxins and mobilan. These drug candidates were designed to activate the immune system to fight cancer and other diseases.

CBLI had a strong reputation in the industry and was recognized for its innovative research and development programs. The company had established partnerships with various research institutions and biopharmaceutical companies to further its drug development programs.

Investing in biopharmaceutical companies like CBLI carries certain risks, including the potential for market fluctuations, regulatory risks, and clinical trial risks. Additionally, the success of a company's therapies is dependent on several factors, including the safety and efficacy of the products and the ability to obtain regulatory approval. Potential investors should carefully consider these risks before making any investment decisions.